Evaluation of apoptosis in human breast cancer cell (MDA-MB-231) induced by ZnO nanoparticles synthesized using Piper betle leaf extract as bio-fuel

• Published in: Applied physics. A, Materials science & processing Vol. 129; no. 6
• Main Authors: Nagarajaiah, Shobha, Nanda, N., Manjappa, Praveen, Nagabhushana, Bhangi Mutta, Gadewar, Manoj, Rao, Srilatha, Krishna, Prashanth Gopala
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.06.2023; Springer Nature B.V
• Subjects: Anticancer properties; Apoptosis; Applied physics; Biocompatibility; Blood; Breast cancer; Characterization and Evaluation of Materials; Condensed Matter Physics; Crystallites; Electron microscopes; Fourier transforms; Hexagonal phase; Infrared analysis; Infrared spectroscopy; Machines; Manufacturing; Materials science; Nanoparticles; Nanotechnology; Optical and Electronic Materials; Physics; Physics and Astronomy; Processes; Spectrum analysis; Surfaces and Interfaces; Thin Films; Toxicity; Zinc oxide; Zinc oxides; Clonogenic assay; Solution combustion; Anticancer activity; Biocompatibility; ZnO nanoparticles; Antioxidant; Apoptosis
• ISSN: 0947-8396; 1432-0630
• DOI: 10.1007/s00339-023-06731-w

In this investigation, zinc oxide nanoparticles (ZnO NPs) were produced by solution combustion-assisted technique utilising aqueous leaf extract of Piper betle (betel leaf) (PB). Phase formation and the particle size of ZnO-PB-NPs were ascertained by using X-ray diffraction. It was observed that the ZnO-PB-NPs crystallize in the hexagonal phase with an average crystallite size of 24 nm. The morphology, shape, and size of the NPs were studied by Scanning Electron Microscope and Transmission Electron Microscope (TEM). The elemental composition was analysed using energy-dispersive advanced X-ray spectroscopy. Further, Fourier-Transform Infrared (FTIR) spectroscopy confirmed the formation of ZnO bonding. Anticancer activity of ZnO-PB-NPs was evaluated in the MDA-MB-231, human breast cancer cells by MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide] assay. The study findings demonstrated that the ZnO-PB-NPs were able to induce significant cytotoxicity in human breast cancer cells in a dose-dependent manner. ZnO-PB-NPs treatment impaired the Clonogenic potential cells of breast cancer. Additionally, the biocompatibility with blood components of ZnO-PB-NPs was evaluated by blood hemolysis assay. It was observed that, ZnO NPs inhibited breast cancer cell growth and increased the induction of early apoptosis cell population.